dgwa.org | NEW DGWA MANDATE
24831
post-template-default,single,single-post,postid-24831,single-format-standard,do-etfw,ajax_fade,page_not_loaded,,select-theme-ver-1.7.1,wpb-js-composer js-comp-ver-5.5.2,vc_responsive

NEW DGWA MANDATE

we are delighted to be working with Recce Pharmaceuticals Limited (ASX: RCE, FWB: R9Q) (“Recce” or “the Company”), to increase investor awareness and broaden the institutional and retail investor base across Europe.

Recce is an Australian based biotech with a global strategy seeking to address the global health challenge of antibiotic resistance superbugs. The medical company’s flagship drug, R327, is being developed to treat blood infections and sepsis.

Dr. John Prendergast, Chairman of Recce Pharmaceuticals Ltd states, “Expanding our focus to the European market presents a wonderful new chapter in our global strategy. The connection of EU biotech and overseas capital aligns well with the Company’s New Classes of Synthetic Anti-Infectives development program.” 

Stefan Müller, CEO of DGWA, comments: “DGWA are delighted to be working with Recce in Europe. Investor interest in quality biotechnology companies is significant and increasing with the global anti-infective market expected to grow at a compound rate of over 30% to 2030 and anticipate the German listing will provide European investors with an opportunity to participate in that growth. We are confident Recce will be warmly welcomed among the European investment community and look forward to supporting their activity in the region over the time ahead.” 

LINK: RECCE PHARMACEUTICALS LIMITED